Report
No Data Yet
**uniQure is reshaping its gene therapy strategy around a faster regulatory path for AMT-130, its Huntington's disease candidate, while narrowing its operating model to pure research and development.** uniQure's AMT-130 gene therapy for Huntington's disease could reach the FDA by the third quarter of 2026 after the agency accepted three-year Phase I/II data as the primary basis for an accelerated approval filing, the company said after a recent Type B meeting. "The FDA's feedback gives us a clearer regulatory path for AMT-130," Matt Kapusta, chief executive officer of uniQure, said. The agency indicated that three-year data from the Phase I/II study could support a biologics license application seeking accelerated approval, though alignment on the confirmatory trial design remains outstanding. The company reported a cash runway extending into the second half of 2029, providing financial flexibility through the regulatory process. Beyond Huntington's, uniQure's pipeline includes AMT-260 for refractory mesial temporal lobe epilepsy, where three of six patients in the first low-dose cohort achieved 79 percent to 100 percent reductions in disabling seizures during months four through six. AMT-191 for Fabry disease showed sustained increases in alpha-galactosidase A enzyme activity and stable Lyso-Gb3 levels, with all 11 dosed patients having discontinued enzyme replacement therapy as of February 18. **Regulatory Path Takes Center Stage** AMT-130 has received Regenerative Medicine Advanced Therapy, Breakthrough Therapy and Fast Track designations from the FDA, reflecting the high unmet need in Huntington's disease, a condition with no approved disease-modifying treatments. The therapy uses uniQure's miQURE gene-silencing platform, employing a microRNA designed to silence the huntingtin gene and the potentially toxic exon 1 protein fragment. The FDA has favored a concurrent standard-of-care control group rather than a sham-controlled trial for the confirmatory study, a detail that shapes the design costs and timeline. uniQure plans to complete regulatory alignment before its targeted third-quarter 2026 submission. PTC Therapeutics, whose PTC518 program has received Fast Track designation for Huntington's disease, and Wave Life Sciences give investors additional reference points in the space. Their presence underscores the competitive landscape uniQure faces as it advances AMT-130 through the regulatory process. **A Leaner Operating Model** uniQure is also simplifying its business structure. After selling its commercial manufacturing business to Genezen in 2024, the company moved in 2026 to transfer HEMGENIX manufacturing responsibilities directly to Genezen. The remaining HEMGENIX supply and minimum purchase commitments are expected to end after delivery of specified batches, with no impact on future royalties or milestone payments from CSL Behring. The result is a more focused research-and-development organization. Sarepta Therapeutics, which has a rare neuromuscular portfolio including gene therapy and exon-skipping treatments in Duchenne muscular dystrophy, shows why execution remains central for genetic medicine companies. **What This Means for Investors** QURE shares have rallied on the clearer regulatory outlook, but the stock's valuation now reflects a higher probability of AMT-130 success. The confirmatory trial design discussions with the FDA will be the next major catalyst, and any delays or design complications could pressure the stock. The pipeline beyond Huntington's — AMT-260 in epilepsy and AMT-191 in Fabry disease — provides optionality but remains early-stage. With cash runway through 2029, uniQure has time to execute, but the next 12 months of regulatory alignment will determine whether the current valuation is justified. This article is for informational purposes only and does not constitute investment advice.
**The FDA's reversal on uniQure's Huntington's disease gene therapy clears a path to accelerated approval, handing the biotech a second chance at a filing it was denied just three months ago.** The U.S. Food and Drug Administration told uniQure that three-year data from a Phase 1/2 study of AMT-130 would be acceptable as the primary basis for an accelerated approval application in Huntington's disease, the company said June 17. The decision marks a sharp reversal from March, when the agency rejected the same data and demanded a placebo-controlled trial before any submission. "The FDA's willingness to accept the three-year analysis reflects an appreciation of the challenges in rare disease following the overhaul of its leadership," Guggenheim Securities analysts said in a note. Former FDA commissioners Marty Makary and Vinay Prasad, who held top positions when uniQure first sought the accelerated path, have since left the agency. UniQure plans to submit the Biologics License Application in the third quarter of 2026. The company's shares surged 80% to $48.51 in premarket trading on the news. The biotech still needs to reach agreement with the FDA on a confirmatory study design, with the agency seeking alignment on using a concurrent control for standard-of-care therapy rather than the previously requested sham procedure. **What the data show** AMT-130 is a gene therapy designed to slow Huntington's disease progression by delivering a gene-silencing mechanism directly to brain cells. In the Phase 1/2 trial, uniQure reported that the therapy slowed disease progression by 75% compared with an external control database of untreated patients, according to CNBC. There are currently no FDA-approved treatments that slow or prevent Huntington's, a fatal genetic disorder that affects about 40,000 Americans, with an estimated 1,383 new privately insured diagnoses annually. The company's approach uses an adeno-associated virus vector to deliver a microRNA targeting the huntingtin gene, the root cause of the disease. This mechanism differs from standard symptomatic treatments, which only manage chorea and other motor symptoms without addressing the underlying neurodegeneration. **Cash runway and dilution risk** UniQure remains lossmaking with modest revenue and relies heavily on AMT-130 as its lead asset. The company recently increased its authorized share capital after shareholders approved changes to its Dutch articles of association, keeping dilution risk on the table as it prepares for a potential launch. Gene therapies for rare diseases typically cost between $2 million and $4.5 million per dose in the U.S., and analysts expect AMT-130 to price near the high end of that range given the absence of disease-modifying alternatives. The confirmatory study requirement adds another layer of execution risk. UniQure said it is "committed to conducting the confirmatory study without delay," though the FDA may require full enrollment before granting accelerated approval. The company's cash position and the timeline for that study will determine whether it can reach the market without additional financing. For investors, the FDA's U-turn resets the risk-reward calculus. If approved, AMT-130 would be the first disease-modifying therapy for Huntington's, addressing a total addressable market of roughly 40,000 U.S. patients. But the stock's 80% surge already prices in a high probability of approval, leaving limited upside if the confirmatory study design proves more burdensome than expected. Rezolute and Regenxbio shares also ticked higher on the news, reflecting hopes that the agency's flexibility on rare disease evidence extends beyond uniQure. This article is for informational purposes only and does not constitute investment advice.